Andrew Clamp (@TheChristieNHS and @OfficialUoM)

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Andrew Clamp to discuss rucaparib maintenance in recurrent ovarian cancer (ARIEL3). Dr. Clamp is an author of “Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3,” the Lead Article for IJGC’s July 2021 issue. Dr. Clamp is a Consultant and Honorary Senior Lecturer in Medical Oncology subspecializing in the treatment of gynaecological cancers. He is Chief Investigator for the MRC ICON8 Trials Programme and leads the gynaecological cancers clinical research team at The Christie.

Highlights

- Rucaparib provides a clinically significant prolongation of progression-free survival when used as maintenance treatment for platinum-sensitive recurrent ovarian cancer.
- In the ARIEL3 trial, rucaparib extended progression-free survival versus placebo regardless of the length of the penultimate platinum-free interval, number of prior chemotherapy regimens or previous use of bevacizumab.
- After extended follow-up, rucaparib was well-tolerated and its safety profile was not impacted by prior treatment history.
- Maintenance PARP inhibitors should be considered for all PARP inhibitor naïve patients with recurrent high grade ovarian cancer after response to platinum-based chemotherapy.